Arbutus Biopharma (ABUS) AI Stock Analysis

• Market Cap: $651.78M
• Dividend Yield: N/A
• Average Volume (3M): 732.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.23
• Revenue Growth: 53.23%
• EPS Growth: 35.32%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 191,698,700
• 10 Day Avg. Volume: 690,102
• 30 Day Avg. Volume: 732,209
• PEG Ratio: 0.64
• Price to Book (P/B): 6.23
• Price to Sales (P/S): 98.35
• P/FCF Ratio: -9.33
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 32.53
• Enterprise Value/Gross Profit: -108.65
• Enterprise Value/Ebitda: -9.25
• 1Y Price Target: $3.50
• Price Target Upside: 2.94% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: $3.50 ▲(2.94% Upside)

Arbutus Biopharma's overall stock score is primarily impacted by its financial challenges, including declining revenues and ongoing losses. However, positive technical indicators and recent corporate events, such as promising treatment data and board changes, provide some optimism. The valuation remains a concern due to negative earnings and lack of dividends.

Positive Factors

Drug Efficacy and Safety

The combination of imdusiran and pegylated interferon alfa-2a was generally safe and well-tolerated, achieving a functional cure in 50% of patients with no serious adverse events.

Financial Management

Arbutus's focus on the efficient deployment of financial resources is driving expectations for a significant reduction in cash burn.

Management and Strategy

The appointment of Lindsay Androski as the new CEO is seen as a strategic move, enhancing the focus on LNP litigation.

Negative Factors

Clinical Trials

Arbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.

Financial Impact

Arbutus anticipates a one-time restructuring charge of approximately $11M-$13M.

Legal Challenges

Arbutus and partner Genevant are expanding their LNP legal activity against Moderna globally, adding complexity to ongoing legal proceedings.

Arbutus Biopharma Business Overview & Revenue Model

Company Description

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with hepatitis B virus (HBV) infections and other viral diseases. The company specializes in discovering and commercializing novel drug candidates that target the underlying biology of HBV to improve patient outcomes. Arbutus's core products include a range of antiviral therapies, particularly those that aim to eliminate HBV or significantly reduce viral load in patients.

How the Company Makes Money

Arbutus Biopharma generates revenue primarily through the development and commercialization of its therapeutic products. The company engages in strategic partnerships and collaborations with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of products developed in collaboration. These partnerships often provide substantial funding for research and development, allowing Arbutus to focus on advancing its clinical trials. Additionally, if any of Arbutus's products receive regulatory approval and are brought to market, the company stands to earn significant revenue from product sales. The company may also explore licensing opportunities for its technologies, further diversifying its revenue streams.

Arbutus Biopharma Financial Statement Overview

Summary

Arbutus Biopharma faces significant financial challenges, with declining revenues, ongoing losses, and negative cash flows. Despite manageable debt levels, consistent unprofitability and cash flow issues present substantial risks, necessitating strategic improvements.

Income Statement

Arbutus Biopharma's income statement shows a declining revenue trend with gross profit margins fluctuating significantly. The company has maintained negative net profit margins, indicating consistent unprofitability. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Although revenue grew slightly in 2020, the overall revenue trajectory is downward, with substantial losses impacting profitability.

Balance Sheet

The balance sheet of Arbutus Biopharma reveals a relatively low debt-to-equity ratio, indicating limited leverage. However, the company's return on equity is negative due to ongoing losses, which is a concern for investors. The equity ratio is moderate, suggesting a balanced asset structure, but the continuous decline in equity due to losses poses risks to financial stability.

Cash Flow

Arbutus Biopharma's cash flow statements highlight negative free cash flow, which has worsened over time, pointing to cash flow challenges. The operating cash flow consistently trails net income, indicating poor cash conversion efficiency. The free cash flow to net income ratio remains negative, suggesting difficulties in generating cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.42M	6.17M	18.14M	39.02M	10.99M	6.91M
Gross Profit	-4.62M	4.79M	-55.56M	37.59M	9.23M	-40.57M
EBITDA	-54.20M	-68.40M	-70.99M	-61.86M	-71.64M	-57.81M
Net Income	-54.25M	-69.92M	-72.85M	-69.46M	-77.35M	-65.21M
Balance Sheet
Total Assets	103.27M	131.71M	144.40M	195.42M	204.49M	137.08M
Cash, Cash Equivalents and Short-Term Investments	98.09M	122.62M	126.00M	146.91M	155.32M	123.27M
Total Debt	1.09M	1.29M	8.72M	2.19M	2.61M	2.98M
Total Liabilities	20.29M	34.34M	38.38M	58.57M	35.05M	35.11M
Stockholders Equity	82.98M	97.37M	106.02M	136.85M	169.44M	101.97M
Cash Flow
Free Cash Flow	-60.28M	-65.03M	-86.94M	-35.87M	-68.34M	-51.67M
Operating Cash Flow	-60.19M	-64.85M	-85.94M	-35.36M	-67.53M	-51.44M
Investing Cash Flow	28.39M	22.95M	50.77M	-74.94M	-12.68M	-14.91M
Financing Cash Flow	6.43M	52.00M	30.65M	31.81M	137.24M	86.75M

Arbutus Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABUS, the sentiment is Positive. The current price of 3.4 is above the 20-day moving average (MA) of 3.26, above the 50-day MA of 3.32, and above the 200-day MA of 3.39, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 58.06 is Neutral, neither overbought nor oversold. The STOCH value of 58.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABUS.

Arbutus Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABCL	57 Neutral	$1.27B	―	-15.64%	―	-0.54%	-6.28%
ABUS	53 Neutral	$651.78M	―	-52.82%	―	53.23%	35.32%
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
XNCR	49 Neutral	$515.67M	―	-29.22%	―	-2.07%	22.52%
PRAX	49 Neutral	$966.84M	―	-60.98%	―	338.45%	-19.64%
NUVB	45 Neutral	$789.53M	―	-64.40%	―	900.35%	70.25%
RCKT	40 Underperform	$308.61M	―	-69.65%	―	―	10.36%

Arbutus Biopharma Corporate Events

Arbutus Biopharma Appoints New Board Member Amid Strong Q2

On August 4, 2025, Anuj Hasija resigned from Arbutus Biopharma‘s Board of Directors, with Dr. Roger Sawhney appointed as his replacement. Dr. Sawhney will also join the Audit and Corporate Governance and Nominating Committees. Arbutus reported strong financial results for the second quarter of 2025, with a significant increase in revenue due to the reacquisition of Greater China rights to imdusiran. The company is actively involved in ongoing patent infringement litigations against Moderna and Pfizer/BioNTech, seeking compensation for the use of its LNP technology.

The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.

Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical

On June 20, 2025, Arbutus Biopharma and Qilu Pharmaceutical mutually agreed to terminate their strategic partnership for the development, manufacturing, and commercialization of imdusiran in Greater China and Taiwan, with all rights reverting to Arbutus. This decision aligns with Qilu’s pipeline reprioritization and Arbutus’ focus on advancing its own pipeline efficiently. Additionally, Arbutus announced the formation of a new Scientific Advisory Board, comprising globally recognized leaders in chronic hepatitis B virus treatment, to guide its strategic evaluation of its cHBV pipeline.

The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.

Arbutus Biopharma Holds Annual Shareholder Meeting

On May 21, 2025, Arbutus Biopharma Corporation held its Annual General Meeting of Shareholders, where shareholders elected the company’s director nominees, approved executive compensation, and appointed Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are pivotal for Arbutus Biopharma’s governance and operational transparency, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.